


Humanetics Corporation Revenue
Pharmaceutical Manufacturing • Bloomington, Minnesota, United States • 11-20 Employees
Humanetics Corporation revenue & valuation
| Annual revenue | $3,500,000 |
| Revenue per employee | $206,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $11,200,000 |
| Total funding | $5,000,000 |
Key Contacts at Humanetics Corporation
Ronald Zenk
Chief Executive Officer And Member Of The Board Of Directors
Jason Brown
Director Of Investor Relations
Ronald Zenk
Chief Executive Officer
Company overview
| Headquarters | 7760 France Avenue South, Suite 920, Minneapolis, MN 55435, US |
| Phone number | +109062023 |
| Website | |
| NAICS | 3254 |
| SIC | 873 |
| Keywords | Pharmaceuticals, Oncology, Inflammation, Medical Countermeasures, Biodefense, Covid-19, Radiation Damage |
| Founded | 1988 |
| Employees | 11-20 |
| Socials |
Humanetics Corporation Email Formats
Humanetics Corporation uses 2 email formats. The most common is {first name}{last name} (e.g., johndoe@humaneticscorp.com), used 55.6% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@humaneticscorp.com | 55.6% |
{first initial}{last name} | jdoe@humaneticscorp.com | 44.4% |
About Humanetics Corporation
Humanetics is a privately held, clinical stage pharmaceutical company located in the Minneapolis metropolitan area. Our lead candidate, BIO 300 is being developed for multiple clinical uses with a primary focus on improving treatment of solid tumor cancers. BIO 300 is being developed as an agent to both sensitize tumor cells to enhance radiation treatment efficacy and to protect normal tissues from harm. Thus, reducing common treatment related side effects such as radiation induced pneumonitis, erectile dysfunction, mucositis and xerostomia. BIO 300 is also under development for inflammatory lung diseases with an immediate focus on mitigation of pulmonary injury due to COVID-19. A recent contract from NIAID will fund a phase 2 study on BIO 300 in recovering COVID patients in an effort to stem progressive long-term lung complications, such as fibrosis. BIO 300 was licensed from the US Department of Defense, where it was originally developed to prevent injuries associated with ionizing radiation. This program is still underway with a focus on prevention of acute radiation syndrome as well as lung injury. For more information about Humanetics, please visit our corporate website at www.humaneticscorp.com.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Humanetics Corporation has 7 employees across 4 departments.
Departments
Number of employees
Funding Data
Explore Humanetics Corporation's funding history, including investment rounds, total capital raised, and key backers.
Humanetics Corporation Tech Stack
Discover the technologies and tools that power Humanetics Corporation's digital infrastructure, from frameworks to analytics platforms.
Web servers
JavaScript libraries
Tag managers
Operating systems
UI frameworks
Analytics
JavaScript libraries
Frequently asked questions
4.8
40,000 users



